Pelthos Therapeutics Inc. (PTHS): auditor change — Channel Therapeutics to merge with LNHC in reverse merger; Ligand to own ~55%

Pelthos Therapeutics Inc.

LNHC valued at $67M; Channel at $15M; combined entity renamed Pelthos Therapeutics Inc.
Post-closing ownership: legacy CHRO 7.7%, Ligand 55.1%, other PIPE investors 37.2%.
PIPE financing of $50.1M from Ligand, Nomis Bay, others; convertible at $1.00/share.
New board includes Scott Plesha (CEO), Francis Knuettel II (CFO); lock-up until Dec 31, 2025.
Auditor changed from Marcum to CBIZ; material weaknesses in internal controls continue.

item 1.01 item 3.02 item 4.01 item 5.07 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Marcum LLP resigned as auditor of Pelthos Therapeutics Inc..

Action: resignation
Auditor: Marcum LLP
Successor: CBIZ CPAs P.C.

Exact text from the filing

On April 11, 2025, Channel was notified by Marcum that Marcum resigned as Channel’s independent registered public accounting firm.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Pelthos Therapeutics Inc. engaged CBIZ CPAs P.C. as its auditor.

Action: engagement
Auditor: CBIZ CPAs P.C.

Exact text from the filing

On April 11, 2025, with the approval of Channel’s Board of Directors, CBIZ was engaged as Channel’s independent registered public accounting firm.

View on SEC.gov

6 auditor changes filed in the last 30 days. Browse all auditor changes →

Pelthos Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001753926-25-000652

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.